Explore by Category

Another Bi-Specific Antibody for Multiple Myeloma Treatment

MYELOMA NEWS - July 01, 2020

It seems that hardly a week goes by without news of progress in the fight against multiple myeloma. This time it comes (again) from Johnson & Johnson, the m... Read More

A New and Different Multiple Myeloma Treatment Option for Triple Refractory Patients

MYELOMA NEWS - July 01, 2020

The Swedish company Oncopeptides announced interesting news, a few days ago, for those of us who have failed prior treatment with immunomodulators and proteasom... Read More

Good News: Long Term Follow Up of Revlimid/Velcade/Dex Use

MYELOMA NEWS - June 28, 2020

We are inundated with snippets of news from a host of clinical studies reporting interesting (and even exciting) results for us, myeloma patients. The caveat wi... Read More

Which Myeloma Drug will You Respond To? Mayo Clinic Scottsdale Researchers Develop New Test

MYELOMA NEWS - June 25, 2020

Myeloma specialists and myeloma patients alike want to know which treatment will work best before they are taken. The Mayo Clinic Scottsdale has developed a new... Read More

Progress on Another CAR -T for Multiple Myeloma!

MYELOMA NEWS - June 22, 2020

It was only a few years ago that the Myeloma Crowd started to post the first articles about CAR-T and the potential promise this medical breakthrough could be f... Read More

EHA 2020: Ixazomib is Effective as Maintenance for Transplant Ineligible Myeloma Patients

MYELOMA NEWS - June 18, 2020

Much of the maintenance therapy used in myeloma care includes immunomodulators like Revlimid or Pomalyst, but a presentation from the European Hematology Associ... Read More

ASCO 2020: CELMoDs as a New Drug Class in Multiple Myeloma

MYELOMA NEWS - June 18, 2020

A new type of myeloma treatment called CC-92480 (a CELMoD) showed benefit in a Phase I international clinical trial at the recent ASCO 2020 meeting.  ... Read More

Tocilizumab and Remdesivir Trial for COVID-19

MYELOMA NEWS - June 17, 2020

A phase III study is now open to study the COVID-19 therapies of tocilizumab alone or with remdesivir for hospitalized patients with severe COVID-19 pneumo... Read More

ASCO 2020: High-Risk Disease Progress Continues Despite Uncertainties

MYELOMA NEWS - June 11, 2020

“Despite the improvements across the board that we’ve seen in myeloma patients, high-risk disease continues to represent a more complicated arena.&r... Read More

ASCO 2020: Genetics Predict Smoldering Myeloma Progression

MYELOMA NEWS - June 11, 2020

A key study shared at the recent ASCO meeting showed that certain genetic features found in myeloma patients could help assess the risk of developing active mye... Read More

ASCO 2020: Mass Spectrometry in MRD Assessment

MYELOMA NEWS - June 03, 2020

Minimal Residual Disease (MRD) testing is used to determine the level of disease following myeloma therapy. It is a more sensitive way of testing very low level... Read More

ASCO 2020: KRD vs. VRD for Newly Diagnosed Multiple Myeloma

MYELOMA NEWS - June 01, 2020

The long awaited interim results of efficacy and toxicity from the phase 3 ENDURANCE trial (E1A11) for Newly Diagnosed Multiple Myeloma failed to show a superio... Read More

ASCO 2020: Various Approaches for Smoldering Myeloma

MYELOMA NEWS - May 29, 2020

The treatment of smoldering myeloma is up for debate and has been for years. In one ASCO session, Sagar Lonial, MD of Emory Winship Cancer Institute showed that... Read More


Thanks to our site sponsors: